HK1

Hexokinase-1 · P19367 · HK1 on Sugi Atlas →

9,074 patent compounds predicted against HK1, 5,964 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1673864	0.49	5/20
SCHEMBL1673868	0.49	5/20
Metrizamide (SCHEMBL24382)	0.41	5/20
Metrizamide (SCHEMBL24383)	0.41	5/20
Metrizamide (SCHEMBL1650311)	0.41	5/20
SCHEMBL374488	0.58	4/20
SCHEMBL2238773	0.56	4/20
SCHEMBL2593594	0.55	4/20
SCHEMBL1302590	0.52	4/20
SCHEMBL1303257	0.52	4/20
N-Acetylglucosamine (SCHEMBL2043188)	0.49	4/20
SCHEMBL1111316	0.47	4/20
Streptozosin (SCHEMBL4748)	0.45	4/20
Streptozosin (SCHEMBL444088)	0.45	4/20
Streptozosin (SCHEMBL444089)	0.45	4/20
Streptozosin (SCHEMBL2351420)	0.45	4/20
Chlorozotocin (SCHEMBL8539)	0.42	4/20
Chlorozotocin (SCHEMBL1648834)	0.42	4/20
Streptozosin (SCHEMBL534373)	0.37	4/20
Streptozosin (SCHEMBL121374)	0.32	4/20

Clinical trials — most relevant to HK1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes	PHASE4	COMPLETED
Alpha Ketoglutarate Enhances Geroprotection In Surgery (AEGIS)	PHASE4	RECRUITING
Ketohexokinase Inhibition in NAFLD	PHASE2	COMPLETED
First-line Irinotecan, Lederfolin and 5FU (FOLFIRI) and Bevacizumab in Patients With Advanced Colorectal Cancer	PHASE2	COMPLETED
A Multi-center 12-week Study of HMS5552 in T2DM	PHASE2	COMPLETED
Safety, Efficacy Evaluation of Empagliflozin Administration for Neutropenia in Glycogenosis Type 1b and G6PC3 Deficiency	PHASE2	UNKNOWN
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes	PHASE2	UNKNOWN
Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLC	PHASE2	UNKNOWN
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers	PHASE2	NOT_YET_RECRUITING
Multiple Ascending Doses of Globalagliatin Hydrochloride in Type 2 Diabetes Mellitus	PHASE1	COMPLETED
The Assessment of Single-Dose Safety,Tolerability, Pharmacokinetics and Pharmacodynamic of Globalagliatin Hydrochloride	PHASE1	COMPLETED
GPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders	PHASE1	NOT_YET_RECRUITING
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers	PHASE1	COMPLETED
Multi-Tracer PET Assessment of Primary Brain Tumors	PHASE1	COMPLETED
3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx	EARLY_PHASE1	COMPLETED
Plasma Mannose Associated Parameter Levels in Nondiabetic Coronary Artery Disease	nan	COMPLETED
Dual PETOvac - Dual Time PET/CT in the Preoperative Assessment of Ovarian Cancer	nan	UNKNOWN
Dried Fruit and Postprandial Glycemia Trial	nan	UNKNOWN
Early Versus Late FDG-PET/CT in Bladder Cancer	nan	COMPLETED
Diagnostic Significance of Single Center, Open and Prospective Evaluation of 18F-FDG PET/CT Dynamic Imaging and Genomic Sequencing in Detecting Metastatic Lesions and Differentiating Multiple Primary Lung Cancer From Intrapulmonary Metastases of Non-small Cell Lung Cancer	nan	UNKNOWN
The Role of Sugars in Fat Accumulation in the Liver	nan	RECRUITING
Effect of Acute Fructose Load in Human	nan	COMPLETED
Utility of PET-MRI in Surveillance of Paediatric Brain Tumours	nan	RECRUITING
18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography in Oncology	nan	COMPLETED
Alternative Substrates in the Critically Ill Subject	nan	COMPLETED
Diagnostic Significance of Single Center, Open and Prospective Evaluation of 18F-FDG PET/CT Dynamic Imaging and Genomic Sequencing in Detecting Metastatic Lesions of Primary Hepatocellular Carcinoma	nan	WITHDRAWN
13C Pyruvate DNP MR Spectroscopy for Lymphoma Treatment Response Assessment	nan	UNKNOWN
Role of the Liver in Glucose Homeostasis Using Metabolic Imaging	nan	COMPLETED
The Role of Pyruvate Kinase M2 in Growth, Invasion and Drug Resistance in Human Urothelial Carcinoma	nan	UNKNOWN
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a HK1 binder may also engage these)

Protein	Name	Similarity
Q5RC71	—	1.000	Q5RC71 →
P05708	—	1.000	P05708 →
P27881	—	1.000	P27881 →
Q91W97	—	1.000	Q91W97 →
A2PYL7	—	1.000	A2PYL7 →
O08528	—	1.000	O08528 →
P27595	—	1.000	P27595 →
Q1W674	—	1.000	Q1W674 →
A2PYL6	—	1.000	A2PYL6 →
P17710	—	1.000	P17710 →
A2PYL8	—	1.000	A2PYL8 →
HK2	Hexokinase-2	1.000	landscape →
HKDC1	Hexokinase HKDC1	1.000	landscape →
P80581	—	0.994	P80581 →
Q9SQ76	—	0.993	Q9SQ76 →
P93834	—	0.993	P93834 →
Q42525	—	0.992	Q42525 →
Q1WM16	—	0.992	Q1WM16 →
Q9SEK2	—	0.992	Q9SEK2 →
GCK	Hexokinase-4	0.992	landscape →
Q3TRM8	—	0.991	Q3TRM8 →
P52792	—	0.991	P52792 →
Q26609	—	0.991	Q26609 →
P17712	—	0.990	P17712 →
Q2KNB7	—	0.989	Q2KNB7 →
Q9FZG4	—	0.989	Q9FZG4 →
Q9NFT7	—	0.989	Q9NFT7 →
P50521	—	0.988	P50521 →
Q9SEK3	—	0.988	Q9SEK3 →
Q969A8	—	0.987	Q969A8 →